Amgen stock faces a USD 400 Cantor Fitzgerald target

Published on 10/05/2026 at 19:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cantor Fitzgerald kept a Neutral view on Amgen at USD 400 on October 5, 2026. Q2 revenue reached USD 10.05 billion, up 9.5 percent year over year.

Editorial-Aufnahme eines Nasdaq-Handelssaals mit großen Bildschirmen und steigenden Biotech-Sektor-Kurscharts — Amgen Inc. (ISIN US0311621009) thematisiert dieses Börsen-Editorial mit Nasdaq-Handelssaal und ansteigenden Biotech-Sektor-Kurscharts auf großen Bildschirmen, Illustration mit AI erstellt.

Amgen stock (ISIN US0311621009) was last at USD 403.25 on Nasdaq at 1:39 p.m. ET on October 5, 2026, while Cantor Fitzgerald reiterated a Neutral rating with a USD 400 price target. The target sits USD 3.25 below the latest Nasdaq price, putting the analyst call close to the market's current level.

Cantor keeps a Neutral view

According to Investing.com on October 5, 2026, Cantor Fitzgerald cited commercial execution while keeping its Neutral assessment and USD 400 target. The report also pointed to positive clinical data in Sjogren's disease and revised expectations for Lp(a) after HORIZON results.

The valuation gap is modest in absolute terms, but the direction matters: the market price was USD 3.25 above Cantor's target during the October 5 session. That leaves the stock positioned between a fresh analyst target and a broader range of views on Amgen's pipeline.

Q2 revenue reached USD 10.05 billion

MarketBeat reported that Amgen's second-quarter 2026 revenue reached USD 10.05 billion, up 9.5 percent from the same quarter a year earlier. The report also said fiscal-year 2026 EPS guidance stood at USD 22.300-23.500, giving investors a defined earnings framework for the year.

The quarterly revenue figure is the stronger operating counterweight to the Neutral rating. It shows that Amgen's commercial base expanded even as analysts weighed competition, clinical execution and the timing of future pipeline catalysts.

Consensus target trails the stock

MarketBeat said the analyst consensus was Hold with an average price target of USD 385.25, based on one Strong Buy, eleven Buy, fifteen Hold and three Sell ratings. At USD 403.25, the Nasdaq price was USD 18.00 above that average target, a wider gap than the Cantor comparison.

Yahoo Finance listed a 52-week range of USD 288.00 to USD 447.03 and a market capitalization of USD 217.896 billion at the October 2, 2026 close. The current intraday price remains USD 43.78 below that 52-week high, or 9.8 percent below it.

Amgen stock stays below its yearly high

Amgen stock was last at USD 403.25 on Nasdaq at 1:39 p.m. ET on October 5, 2026, up 0.05 percent on the session. Its market capitalization was USD 217.6 billion, while the 52-week range stood at USD 288.00 to USD 447.03.